Impact of bisphosphonates on the risk of atrial fibrillation

American Journal of Cardiovascular Drugs

Volumn 10, Issue 6, 2010, Pages 359-367

  Howard, Patricia A ^a   Barnes, Brian J ^a   Vacek, James L ^a   Chen, Warren ^a   Lai, Sue Min ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation, drug induced; Atrial flutter, drug induced; Bisphosphonates, adverse reactions.

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE; DRUG MECHANISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HIP FRACTURE; HUMAN; HYPERTENSION; INFLAMMATION; META ANALYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; SAMPLE SIZE; SMOKING; STROKE; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

ATRIAL FIBRILLATION; DIPHOSPHONATES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 78649374341     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11584720-000000000-00000     Document Type: Review

References (32)

1. Owens G. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007; 13: S290-308
2. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-60
3. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006; 368: 973-4
4. Black DM, Delmas PD, Eastell R, et al., for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22
5. Cummings SR, Schwartz AV. Alendronate and atrial fibrillation (letter). N Engl J Med 2007; 356: 1895-6
6. Early communication of an ongoing safety review on bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). 1 Oct 2007 [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/ucm150837.htm [Accessed 2009 Jun 17]
7. Update of safety review follow-up to the October 1 2007 early communication about the ongoing safety review of bisphosphonates. 12 Nov 2008 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm136201.htm [Accessed 2010 Apr 16]
8. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis (letter). N Engl J Med 2007; 357: 712-3
9. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809
10. Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with an oral bisphosphonate. J Intern Med 2009; 265: 581-92
11. Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risks of developing atrial fibrillation. Am J Cardiol 2009; 103: 824-8
12. Vestergaard P, Schwartz K, Pinholt E, et al. Riskof atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010; 86: 335-42
13. Huang W, Tsai Y, Wen Y, et al. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 2010; 17: 57-63
14. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008; 336: 813-6
15. Grosso A, Douglas I, Hingorani A, et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE 2009; 4 (3): e4720
16. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168: 826-31
17. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009; 32: 219-28
18. Bhuriya R, Singh M, Molnar J, et al. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010 Jan. Epub ahead of print
19. Kim SY, Kim MJ, Cadarette SM, et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010 Feb 19; 12: R30. Epub ahead of print
20. Mak A, Cheung M, Ho R, et al. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet al Disorders 2009; 10: 113
21. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10
22. Pazianas M, Compston J, Huang CL-H. Atrial fibrillation and bisphosphonate therapy. J Bone Min Res 2010; 25: 2-10
23. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gammadelta T cells in response to aminobisphosphonates is inhibited by statin. Clin Exp Immunol 2005; 139: 101-11
24. Van Wagoner DR, Nerbonne JM. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 2000; 32: 1101-17
25. Poole KE, Kaptoge S, Reeve J. Yearly zoledronic acid in postmenopausal osteoporosis (letter). N Engl J Med 2007; 357: 711-2
26. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001; 38: 608-23
27. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphophonate therapy in occult vitamin D deficiency. N Engl J Med 2003; 348: 1503-4
28. Poole KE, Loveridge N, Rose CM, et al. A single infusion of zoledronate prevents bone loss after stroke. Stroke 2007; 38: 1519-25
29. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
30. Black D. Yearly zoledronic acid in postmenopausal osteoporosis (letter). N Engl J Med 2007; 357: 711-2. 714
31. Singer DE, Albers GW, Dalen DE, et al. Antithrombotic therapy in atrial fibrillation. Chest 2008; 133: 546S-92S
32. Majumdar SR. Oral bisphosphonates and atrial fibrillation (editorial). BMJ 2008; 336: 784-5